Australia markets closed

Mustang Bio, Inc. (MBIO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.2600+0.0100 (+0.80%)
At close: 04:00PM EST
1.2900 +0.03 (+2.38%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Previous close1.2500
Open1.2900
Bid1.2100 x 1000
Ask1.2900 x 2900
Day's range1.2400 - 1.3000
52-week range1.2100 - 8.6550
Volume31,823
Avg. volume56,575
Market cap11.614M
Beta (5Y monthly)1.63
PE ratio (TTM)N/A
EPS (TTM)-8.9300
Earnings date27 Mar 2024 - 01 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.33
  • GlobeNewswire

    Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference

    WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference, takin

  • GlobeNewswire

    Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting

    Data showed favorable safety profile, complete response rate and durability in the treatment of patients with relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma 100% of patients with follicular lymphoma achieved a complete response; no occurrence of CRS above grade 1 and no ICANS of any grade Complete responses observed in patients previously treated with CD19-targeted CAR T-cell therapy Outpatient administration found to be feasible WORCESTER, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) -- M

  • GlobeNewswire

    Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

    WORCESTER, Mass., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the third quarter that ended September 30, 2023. Manuel Litchman, M.D., President and Chief Executive Officer of Mustang, said, “I